Medixo Centre

Enzalutamide was jointly developed by Pfizer and Astellas. It was approved by the US FDA on August 31, 2012 for the treatment of metastatic adenocarcinoma. For resistant prostate cancer, the drug is branded as XTANDI. The drug is an oral preparation and does not require genetic testing before use. You can order it online from Medixo Centre at best cost.